Coherus BioSciences (CHRS) Reports Q3 Loss Per Share of $1.86
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $0.85 +4.94%
Revenue Growth %: +37.8%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +37.8%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($1.86), versus ($1.79) reported last year. Revenue for the quarter came in at $7.2 million, versus $16.1 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Applovin shares surge on strong Q3 results and guidance
- 3D Systems (DDD) Misses Q3 EPS by 1c
- Western Midstream Partners, LP (WES) Misses Q3 EPS by 14c; reaffirms guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
